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Mountain and maritime climate therapy takes advantage of specific climatic conditions to treat chronic allergic
diseases. It was the aim of the study to investigate effects of a 5 day sojourn on atopic diseases at the highest
German mountain. In this pilot study 18 patients with grass pollen-induced rhinoconjunctivitis, atopic ezcema or
asthma and 11 non-allergic controls were included. Skin physiology parameters, changes of the respiratory and
nasal functions, subjective symptoms and blood parameters were measured during a 5-day observation period in
the Environmental Research Station Schneefernerhaus (UFS) at the moderate altitude mountain region (Zugspitze;
2650 m alt.) compared to a low altitude area (Munich; 519 m alt.). Several of the skin physiology parameters
changed significantly during the observation period (decrease of skin hydration, increase of skin smoothness, skin
roughness, skin scaliness and pH-value). In patients with atopic eczema, the SCORAD (Severity Scoring of Atopic
Dermatitis) and the scores of the DIELH (Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen)
did not change significantly. Histamine induced itch decreased significantly. Parameters of nasal function did not
change significantly. Several lung parameters showed a slight, but statistically significant improvement (forced
expiratory volume in one second/volume capacity [FEV1/VC], peak expiratory flow [PEF], maximum expiratory flow
at 50% of vital capacity [MEF 50], maximal mid-expiratory flow between 25% and 75% of vital capacity [MMFEF
25/75]), whereas the vital capacity (VC) decreased significantly. ECP (eosinophil cationic protein) in the serum and
parameters of blood count changed significantly. These results show that the benefit of a moderate altitude
mountain climate sojourn over a period of 5 days differs in depending on the atopic disease. Especially asthma
parameters and itching of the skin improved. It would be interesting to assess the parameters during longer
observation periods in alpine climate.
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Climate therapy comprises the use of certain climatic
conditions in the treatment of chronic diseases. In al-
lergy, maritime and moderate altitude mountain zones
are of interest [1,2]. It was the aim of this pilot study to
follow objective and subjective parameters in patients
suffering from rhinoconjunctivitis and/or atopic eczema
and asthma over a 5 days sojourn in the Environmental
Research Station Schneefernerhaus (UFS) at the Zugspitze
(2650 m alt.) in the alpine mountain climate of Bavaria
compared to lowland in Munich (518 m alt.).
18 patients (6 males, 12 females; mean age: 26 years,
range: 18–32 years) with grass-pollen induced rhinocon-
junctivitis, atopic eczema or asthma and 11 non-allergic
controls (4 males, 7 females; mean age: 30 years, range
24–43 years) were included in the study. Characteristics





Sex Atopic disease Prick-test (positive)
01 31 f Asthma, AR Birch, grass, cat, celery
02 25 f AR D. pter., birch, grass, mugwort
03 25 f AR D. pter., cat, grass, mugwort
04 31 f AR Hazel, celery, Alt. alternata
05 23 f Asthma, AR D. pter., birch, dog, cat
06 24 f AE, Asthma, AR Grass
07 24 f AE, Asthma Trees, mugwort, birch, D. pter.,
grass, hazel
08 30 m AE, AR Trees, birch, D. pter., alder, gras
hazel, dog, cat
09 28 m AR Trees, mugwort, birch, Blatella,
D. pter., alder, grass, hazel, dog,
ambrosia, herbage
10 25 f AD Grass, cat, herbage
11 18 m Asthma D. far., D. pter., grass
12 20 m AE, Asthma, AR Trees, birch, D. far., D. pter., alde
hazel, Aspergillus, Ambrosia
13 20 f AE, Asthma Negative
14 27 m AE, Asthma, AR Trees, birch, D. pter., alder, gras
dog, cat, horse, Alternaria tenui
Ambrosia
15 24 f AE, Asthma, AR Trees, birch, D. far., D. pter., alde
grass, hazel, dog, cat, herbage,
16 26 f AD Mugwort, grass, herbage
17 32 m AR Trees, birch, alder, grass, herbag
Ambrosia
18 28 f Asthma, AR Trees, birch, D. far., D. pter., alde
grass, hazel, herbage,
Abbreviations: AD atopic diathesis, AE atopic eczema, AR allergic rhinitis, D. far. Derm
m male.Five-day observation periods at the Environmental Re-
search Station Schneefernerhaus (UFS) were performed
at the following time points with groups up to 10 pa-
tients and/or controls: July/August 2008, March 2009
and July 2009. All parameters were measured 3 to 4 days
in Munich before the sojourn at the UFS (t1), at the first
and second day (t2) and at the fourth and fifth (t3) day
during the sojourn at the UFS as well as about 4 weeks
later in Munich (t4). The local Ethical Committee ap-
proved the study (Ethik-Kommission der Bayerischen
Landesärztekammer, No. 08054). All participants had
given informed consent. All parameters were measured
in all patients (exception: SCORAD only in patients with
atopic eczema) and controls (exceptions: skin prick test
titration, SCORAD, conjunctival provocation).
The severity of the atopic eczema was graded accord-




275 D. pter. 2, cat 2, dog 3, hazelnut 2, celery 1, grass 4,
birch 4, hazel 3
964 D. pter. 3, celery 3, grass 6, birch 4, hazel 5, wheat
flour 3, rye 5, mugwort 3
79.4 D. pter. 3, cat 1, grass 2, rye 2, mugwort 2
14.2 Grass 2
134 D. pter. 4, cat 2, dog 2, grass 3
161 D. pter. 5, grass 2, mugwort 1, Ambrosia 1
alder, 2248 D. pter. 4, cat 3, celery 3, grass 3, birch 5, wheat
flour 3, mugwort 3, Ambrosia 3, latex 2
s, 1822 D. pter. 6, cat 4, grass 5, birch 3, wheat flour 1,
mugwort 1, milk 2
D. far.,
cat,
226 D. pter. 4, cat 2, hazel nut 3, grass 2, birch 3,
mugwort 2, Ambrosia 1
113 Cat 3, grass 4
493 D. pter. 2, grass 5, Ambrosia 1




1455 D. pter. 3, cat 5, grass 3, birch 6, wheat flour 2,




159 D. pter. 4, cat 2, grass 2, birch 3
8.7 Grass 3
e, 142 D. pter. 1, cat 2, grass 4, birch 2, wheat flour 1,
Ambrosia 2
r, 77.5 D. pter. 3, celery 1, grass 3, birch 4, Ambrosia 2
atophagoides farinae, D. pter. Dermatophagoides pteronyssinus, f female,
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performed in patients at all time points and the wheal
and flare reactions were measured. Itch intensity after
prick testing of histamine was rated on a computerized
visual analogue scale (VAS).
Parameters of skin physiology (surface pH, sebum, skin
hydration) were measured on the flexor side of the forearm
with a Corneometer (CORNEOMETER CM825/SEBUME
TER SM 810/SKIN-pH-METER PH 900 KOMBI, Courage
and Khazaka electronic GmbH, Köln, Germany).
Transepidermal water loss (Tewameter TM 300; CK
electronic GmbH, Köln, Germany) was measured in unex-
posed skin and 10 min after exposure to a 0.5 M NaOH
solution (alkali resistance test) and 0.9% NaCl solution 2
times for 10 min with an interval of 10 min in between.
Laser Doppler imaging (Moor Instruments, Axminster,
England) was applied to monitor dermal blood flow.
Application of skin replicas was done according to
previous publications [4]. Replicas were measured by
means of the optical skin measuring system VisioScan
VC98 with the software SELS 2000 (Courage and Kha-
zaka electronic GmbH, Köln, Germany) calculating skin
surface parameters.
In all subjects rhinomanometric and pulmonary function
parameters were determined with a spirometer (Flowsc-
reen Pro, Jaeger GmbH, Hoechberg, Germany) and a
methacholine challenge test was performed with a body-
plethysmograph (Master Screen Body, Jaeger GmbH,
VIASYS Healthcare, Hoechberg, Germany) as previ-
ously described [5]. Peak-flow monitoring was done
with peak-flow-meters (Mini-Wright-Peak-Flow-Meter,
Clemente Clark, Essex, England). FENO measurements
(NIOX MINO; Aerocrine, Solna, Sweden) were per-
formed at the different time points as previously de-
scribed [6].
Nasal secretions were collected by placing small cotton
wool pieces into the middle meatus ot the nose for
20 minutes, followed by centrifugation (3000 R, 20 min)
of the cotton wool pieces. In all samples ECP was ana-
lyzed (CAP ECP FEIA, Pharmacia, Uppsala, Sweden).
In the conjunctival provocation test five serial dilutions
(1:10) of grass pollen extracts were created. A single
drop (20 μl) of the lowest concentration was placed in
the conjunctival sac followed by the next concentration
at 10-min intervals switching from one eye to the other
until symptoms appeared. Symptoms were scored as
absent (0,) mild (1), moderate (2) or severe (3) 5 and
10 min after challenge.
The following questionnaires were used: Deutsches In-
strument zur Erfassung der Lebensqualität bei Hauterk-
rankungen (DIELH), a questionnaire for health related
quality of life (SF-36), The Eppendorf Itch Questionnaire
(EIQ) in adults) and the Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ) [7-10].The following blood parameters were determined: com-
plete blood count (Sysmex XT-2000 i/XT-1800i; Sysmex
Corporation, Japan), eosinophil cationic protein (CAP ECP
FEIA, Pharmacia, Uppsala, Sweden), human IL-16 (DuoSet
ELISA Development System, R&D Systems Europe,
Abingdon, United Kingdom) and IL-33 (Human IL-33
ELISA Quantitation Kit, Gentaur, Brussels, Belgium).
Data were analyzed using SPSS. For statistical analysis
of the whole study population the Friedman’s one-way
analysis of variance by ranks was used for paired sam-
ples and the Wilcoxon test for unpaired samples. For the
disease-related analysis the univariate analysis of vari-
ance (ANOVA) was used. The critical value for signifi-
cance was set at P < 0.05 for all analyses.
Several of the skin physiology parameters worsened
significantly during the observation period at the Enviro-
mental Research Station Schneefernerhaus (UFS), e.g. skin
hydration (decreased; p < 0.01), skin smoothness (increased;
p < 0.01), skin roughness (increased; p < 0.05), skin scaliness
(increased; p < 0.01) and pH-value (increased; p < 0.01). For
details see Table 2. Histamine induced itch decreased
significantly (Figure 1). The score of the RQLQ improved
significantly (p < 0.05). Several lung parameters showed a
slight, but statistically significant (p < 0.05) improvement
(FEV1/VC, PEF, MEF 50, MMFEF 25/75), whereas the vital
capacity (VC) decreased significantly (p < 0.05). Values of
the measurement of fractional exhaled nitric oxide (FeNO)
did not differ significantly at the different time points. In
the serum a significant decrease (p < 0.01) of ECP was
found at the beginning of the stay at the UFS versus the
first assessment in Munich (t2 vs. t1) and again a significant
increase for ECP (p < 0.01) at the last assessment in Munich
versus the end of the stay at the UFS (t4 vs. t3). Parameters
of blood count changed significantly. Data for IL-33 were
too low to compare.
This study shows, that a 5-day-sojourn at the Environ-
mental Research Station Schneefernerhaus (UFS Zugspitze)
at an altitude of 2650 m alt. exerts different effects on
atopic diseases. A limitation of the study is the small num-
ber of participants.
Despite benefits of climate therapy in patients with
atopic eczema during treatment in specialized in-patient
facilities in the alpine mountain climate of Bavaria [11,12]
or in mountain altitude conditions like Davos [1] we didn’t
find a clinical amelioration of atopic eczema skin lesions
using the SCORAD. Moreover some skin physiology pa-
rameters worsened (e.g. stratum corneum hydration, pH,
skin roughness). On the one hand this might be due to
the fact that topical glucocorticosteroids were withdrawn
1 week before time point 1, on the other hand side low air
humidity at this altitude might have negative influences
on the skin. Only histamine-induced itching showed a sig-
nificant improvement during the observation period at the
UFS. It is known that in the Swiss mountain area of Davos
Table 2 Significant results of skin, nasal, conjunctival and lung parameters, questionnaires and blood parameters at the beginning (t1) in Munich, at time
point 2 (t2) and 3 (t3) in the UFS and time point 4 (T4) in Munich in the different groups: data are means ± SD
Parameter t1 (pat.) t1 (contr.) t2 (pat.) t2 (contr.) t3 (pat.) t3 (contr.) t4 (pat.) t4 (contr.) Wilcoxon ANOVA
Skin parameters
Str. corneum hydration (arb. units) 46±10 48±7 36±8 39±6 38±7 39±5 44±14 47±4 **t1/t2 **t3/t4
PH 4.9±1.3 5.2±1.2 5.9±1.3 5.4±1.2 5.9±1.3 5.4±1.2 5.2±1.3 4.5±1.2 **t1/t2 **t3/t4
Skin roughness (arb. units) 0.6±0.3 0.5±0.2 1.0±0.3 0.6±0.2 0.6±0.4 0.5±0.2 0.6±0.4 0.5±0.2 *t1/t2 **t3/t2
Skin scaliness (arb. units) 0.3±0.2 0.3±0.2 0.7±0.3 0.7±0.4 0.8±0.3 0.6±0.3 0.6±0.3 0.5±0.2 **t1/t2 **t3/t4
Skin smoothness (arb. units) 18.2±2.0 18.2±3.8 21.0±3.8 18.8.±4.4 22.3±4.3 18.5±4.3 19.0±2.9 15.1±0.5 **t1/t2 **t3/t4 ↓AE t1/t2
TEWL (g/(hm2)) 8.0±5.0 6.0±1.4 6.2±2.5 5.9±1.2 7.1±3.8 7.0±1.8 9.8±9.2 7.5±2.2 ↑AE t3/t4
Blood flow (right) (arb. units) 109±23 96±16 n.d. n.d. 121±49 97±19 108±15 98±16 ↑AE t1/t3
Blood flow (left) (arb. units) 115±28 98±15 n.d. n.d. 124±60 96±23 113±28 101±20 ↑AE t1/t3 ↓AEt3/t4
Wheal diluted 1:10 (mm) 6.2±2.9 n.d. 5.7±2.3 n.d. 6.1±2.6 n.d. 4.9±1.6 n.d. ↑AR t1/t2
Wheal diluted 1:100 (mm) 2.9±1.1 n.d. 2.9±1.1 n.d. 3.6±1.2 n.d. 2.8±1.0 n.d. *t2/t3
Flare diluted 1:10 (mm) 31.3±10.1 n.d. 25.1±10.8 n.d. 23.4±8.5 n.d. 25.0±9.6 n.d **t1/t2
Nasal and conjunctival parameters




0.7±0.5 n.d. 0.4±0.5 n.d. 0.5±0.5 n.d. 0.6±0.5 n.d. ↑Asthma t1/t2
↓Asthma t2/t3
Lung parameters
FVC (l) 5.1±1.7 4.6±1.0 5.2±2.0 5.0±1.3 4.6±1.2 4.7±1.2 4.7±1.5 5.0±1.0 *t2/t3
FEV1/VC (%) 78±15 88±12 80±17 89±8 85±11 90±7 81±14 89±9 *t1/t3
PEF (l/s) 9.1±2.9 10.0±2.63 10.1±2.5 11.2±3.0 9.6±2.5 10.9±2.9 9.9±2.7 10.2±2.4 **t1/t2 **t2/t3 *t3/t4
MEF50 (l/s) 4.26±1.7 5.35±2.0 4.76±2.0 5.84±2.1 4.85±1.9 5.60±1.8 4.67±1.5 5.5±1.4 *t1/t2
MMEF 25/75 (l/s) 3.75±1.5 4.73±1.6 4.23±1.8 5.19±1.8 4.22±1.6 5.02±1.6 4.25±1.1 5.02±1.1 **t1/t2
Resistance after 0.1% methacholine
(kPA*s/l)
0.33±0.1 0.23±0.02 0.42±0.2 0.31±0.2 0.52±0.2 0.24±0.1 n.d. n.d. **t1/t2 **t1/t3 ↓Asthma t1/t2 ↑AE t1/t2
FeNO (ppb) 41.6±34.6 17.6±7.9 32.0±24.9 12.8±10.2 38.2±34.3 20.0±15.4 33.2±26.5 16.2±9.3
Questionnaires
DIELH (score) 30±30 1±1 27±30 1±1 29±29 1±2 24±28 0±1 ↑AE t1/t2
RQLQ (score) 5.6±0.9 6.6±0.3 5.6±1.0 6.8±0.2 5.8±0.9 6.8.±0.2 5.7±0.9 6.6±0.3 *t1/t3 ↓Asthma t2/t3 ↑AE t2/t3
SF-36 (score) 2.2±0.4 2.0±0.4 2.2±0.4 2.0±0.5 2.2±0.4 2.0±0.5 2.4±0.2 2.2±0.2 ↓AR t2/t3
Blood parameters
Erythrocytes (106/μl) 4.85±0.4 4.85±0.6 5.27±0.5 5.09±0.92 4.92±0.42 4.86±0.57 5.01±0.37 4.79±0.4 **t1/t2 **t2/t3 ↓AR t2/t3
















Table 2 Significant results of skin, nasal, conjunctival and lung parameters, questionnaires and blood parameters at the beginning (t1) in Munich, at time
point 2 (t2) and 3 (t3) in the UFS and time point 4 (T4) in Munich in the different groups: data are means ± SD (Continued)
Hematocrit (%) 42.9±3.7 42.3±4.5 46.6±4.6 44.3±6.7 43.4±3.6 42.6.0±4.0 44.8±3.2 43.0±2.90 **t1/t2 *t2/t3 ↓AR t2/t3
Eosinophils (%) 4.0±3.1 1.9±1.3 4.3±2.9 2.0±1.2 4.9±3.1 3.1±1.8 4.2±3.1 2.3±1.1 **t1/t3
Basophils (%) 0.5±0.2 0.4±0.2 0.4±0.2 0.3±0.2 0.5±0.2 0.5±0.2 0.5±0.2 0.3±0.20 **t1/t3
ECP (μg/ml) 16.0±11.0 6.0±4.0 5.0±5.0 2.0±2.0 11.0±11.0 6.0±6.0 14.0±9.0 5.0±3.0 **t1/t2 **t2/t3 **t3/t4
IL-33 (ng/ml) 2.96±4.04 4.16±5.98 2.81±4.1 4.0±5.92 2.72±3.91 3.72±5.97 1.85±2.45 5.16±.6.94 *t1/t2 ↑Asthma t3/t4
Abbreviations: AE atopic eczema, AR allergic rhinitis, arb. units arbitrary units, contr. controls, DIELH Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen, ECP eosinophil cationic protein, FeNO
fractional exhaled nitric oxide, FEV1/VC forced expiratory volume in one second/volume capacity, FVC forced volume capacity, MEF50 maximum expiratory flow at 50% of vital capacity, MMEF 25/75 maximal
mid-expiratory flow between 25% and 75% of vital capacity, n.d. not done, pat. patients, PEF peak expiratory flow, ppb parts per billion, RQLQ Rhinitis Quality of Life Questionnaire, prov. provocation, Str. stratum,

































Figure 1 Mean of itch intensity after skin prick test with histamine of patients and controls at the different time points (Munich: time
point 1 (t1) and time point 4 (t4); UFS: time point 2 (t2) and time point 3 (t3)). **p < 0.01 (t2 vs. t1); *p < 0.05 (t3 vs. t2).
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teorological variables, especially air temperature [13].
An improvement of several lung parameters was ob-
served, only the forced vital capacity decreased. There
are several studies showing that FVC decreases with in-
creasing altitude. It is assumed that this effect is related
to pulmonary interstitial changes due to pulmonary ar-
tery enlargement and interstitial edema [14]. Improve-
ment of other lung function disturbances had also been
reported in previous studies with children and adoles-
cents in in-patient rehabilitation programs [15-18] in
moderately and high mountain climate. This may be due
to a reduced allergen exposure in the altitude. House
dust mites allergens haven’t been measured during this
study, but it is known that mites can not survive in alpine
mountain climate above 1500 m. Furthermore it could be
shown that in general the amount of pollen (birch, grass)
at the UFS is considerably lower than the amount in Mun-
ich (unpublished observations, Buters J et al.). Decrease of
exhaled NO as a parameter of lung inflammation was also
seen in asthmatic patients under mountain climate ther-
apy [6], but not in our study. This may be due to the short
time period at the UFS.
In the AURA (Allergien und Umweltkrankheiten in
der Rehabilitation) study we found a significant increase
of the SF-36 questionnaire confirming the benefit of the
therapy in Pfronten [11], but in our study at the UFS
there were no significant differences at the different time
points. Also the skin specific questionnaires emphazising
the pruritus (The Eppendorf Itch Questionnaire) and the
quality of life (DIELH) showed a significant drop of the
total score in the DIELH in the AURA study [11], but in
our study these scores did not differ significantly. This dis-
crepancy may be due to additional therapies (e.g. optimized
therapy with glucocorticosteroids and systemic drugs) andtrainings (e.g. special trainings for patients with asthma
and atopic eczema) offered in a clinical department.
As expected exposure to moderate altitude had signifi-
cant effects on red blood cells [19]. We could show an
increase of eosinophils during the stay at the UFS. This
is in contrast to other studies during hospital treatment
of atopic eczema in the mountain climate [20] and the
North Sea climate with decreased eosinophils [21].
Elevated ECP levels are regarded as markers of inflam-
mation in asthma and atopic eczema [22]. A decrease of
ECP had been shown in the mountain climate of Davos
[23]. In our study, in patients with atopic diseases ECP
decreased significantly from time point t1 to time point
t2, but increased again at time point t3. This may reflect
the aggravation of the skin parameters. It could be shown
that circulating Il-16 levels are correlated with the
SCORAD in adult patients with atopic eczema [24] and
decreased significantly in these patients after successful
treatment [25]. According to this, we did not find a de-
crease in our patients with atopic diseases.
The 5 day observation period in the mountain climate of
the Zugspitze in Bavaria showed favourable results only for
a limited number of parameters. Especially patients with
asthma had a benefit from this stay, whereas skin physi-
ology parameters worsened. This might be due to the short
duration of the sojourn and typical environmental factors
at this altitude. This pilot study suggests that it would be of
interest to assess the skin parameters and characteristics of
atopic eczema over a longer period of observations.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BE, RF, UD, HB, RH, JR have made substantial contributions to the conception
and design of the study. RH, JHM, FP, RF, MS, JL, ML, VA, JL, CE, JB have
made substantial contributions to the acquisition of the data. MK, RH, JL
Eberlein et al. Clinical and Translational Allergy 2014, 4:17 Page 7 of 7
http://www.ctajournal.com/content/4/1/17have made substantial contributions to the analysis of the data. BE and JR
have been involved in drafting the manuscript. All other authors revised it
critically, gave final approval and agreed to be accountable for all aspects of
the work.
Acknowledgement
The statistical analysis was performed by the Institut für Medizinische Statistik
und Epidemiologie, Technische Universität München (Bernhard Haller).
The authors also want to thank the Free State of Bavaria (Bayerisches
Staatsministerium für Umwelt und Gesundheit) for funding and the Christine
Kühne Center for allergy research and education (CK – CARE) for support in
data evaluation.
Author details
1Department of Dermatology and Allergy Biederstein, Technical University
Munich, Munich, Germany. 2Center of Allergy and Environment (ZAUM,
Zentrum Allergie und Umwelt), Technische Universität and Helmholtz Center,
Munich, Germany. 3Division of Respiratory Medicine Campus Innenstadt,
Ludwig-Maximilians-Universität München, Munich, Germany.
Received: 3 March 2014 Accepted: 25 March 2014
Published: 8 May 2014
References
1. Steiger T, Borelli S: Significance of climatic factors in the treatment of
atopic eczema (Atopic Constitutional Neurodermitis). In Handbook of
Atopic Eczema. Edited by Ruzicka T, Ring J, Przybilla B. Berlin, Heidelberg,
New York: Springer; 1991:420–428.
2. Karagiannidis C, Hense G, Rueckert B, Mantel PY, Ichters B, Blaser K, Menz G,
Schmidt-Weber CB: High-altitude climate therapy reduces local airway
inflammation and modulates lymphocyte activation. Scand J Immunol 2006,
63:304–310.
3. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A: Clinical validation
and guidelines for the SCORAD index: consensus report of the European
Task Force on Atopic Dermatitis. Dermatology 1997, 195:10–19.
4. Eberlein-König B, Schäfer T, Huss-Marp J, Darsow U, Möhrenschlager M,
Herbert O, Abeck D, Krämer U, Behrendt H, Ring J: Skin surface pH, stratum
corneum hydration, trans-epidermal water loss and skin roughness
related to atopic eczema and skin dryness in a population of primary
school children. Acta Derm Venereol 2000, 80:188–191.
5. Fischer R, Lang SM, Bergner A, Huber RM: Monitoring of expiratory flow
rates and lung volume during a high altitude expedition. Eur J Med Res 2005,
10:469–474.
6. Huss-Marp J, Krämer U, Eberlein B, Pfab F, Ring J, Behrendt H, Gulyas AF:
Reduced exhaled oxide values in children with asthma after inpatient
rehabilitation at high altitude. J Allergy Clin Immunol 2007, 120:471–472.
7. Schäfer T, Staudt A, Ring J: German instrument for the assessment of
quality of life in skin diseases (DIELH). Internal consistency, reliability,
convergent and discriminant validity and responsiveness. Hautarzt 2001,
52:624–628.
8. Ware JJ, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey. Manual and
interpretation guide. Boston: The Health Institute, New England Medical
Center; 1993.
9. Darsow U, Mautner VF, Bromm B, Scharein E, Ring J: The Eppendorf
Pruritus Questionnaire. Hautarzt 1997, 48:730–733.
10. Juniper EF, Guyatt GH: Development and testing of a new measure of
health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991,
21:77–83.
11. Eberlein B, Gulyas A, Schultz K, Lecheler J, Flögel S, Wolfmeyer C, Thiessen K,
Gass S, Kroiss M, Huss-Marp J, Darsow U, Hollweck R, Schuster T, Behrendt H,
Ring J: Benefits of alpine mountain climate of Bavaria in patients with
allergic diseases and chronic obstructive pulmonary disease: results
from the AURA study. J Investig Allergol Clin Immunol 2009, 19:159–161.
12. Eberlein B, Gulyas A, Schultz K, Lecheler J, Flögel S, Wolfmeyer C, Thiessen K,
Jakob T, Hollweck R, Ring J, Behrendt H: Domestic allergens and endotoxin in
three hospitals offering in-patient rehabilitation for allergic diseases in the
alpine mountain climate of Bavaria – the AURA study. Int J Environ Health 2009,
212:21–26.
13. Vocks E, Busch R, Fröhlich C, Borelli S, Mayer H, Ring J: Influence of weather
and climate on subjective symptom intensity in atopic eczema.
Int J Biometeorol 2001, 45:27–33.14. Ziaee V, Alizadeh A, Movafegh A: Pulmonary function parameters changes
at different altitudes in healthy athletes. Iran J Allergy Asthma Immunol 2008,
7:79–84.
15. Petermann F, Gulyas A, Niebank K, Stübing K, Warschburger P:
Rehabilitationserfolge bei Kindern und Jugendlichen mit Asthma
und Neurodermitis. Allergologie 2000, 23:492–502.
16. Grootendorst DC, Dahlen SE, van den Bos JW, Duiverman EJ,
Veselic-Charvat M, Vrijlandt EJLE, O’Sullivan S, Kumlin M, Sterk PJ, Roldaan AC:
Benefits of high altitude allergen avoidance in atopic adolescents with
moderate to severe asthma, over and above treatment with high dose
inhaled steroids. Clin Exp Allergy 2001, 31:400–408.
17. van Velzen E, van den Bos JW, Benckhuijsen JA, van Essel T, de Bruijn R,
Aalbers R: Effect of allergen avoidance at high altitude on direct and
indirect bronchial hyperresponsiveness and markers of inflammation in
children with allergic asthma. Thorac 1996, 51:582–584.
18. Rijssenbeek-Nouwens LH, Bel EH: High-altitude treatment: a therapeutic
option for patients with severe, refractory asthma? Clin Exp Allergy 2011,
41:775–782.
19. Schmidt W: Effects of intermittent exposure to high altitude on blood
volume and erythropoietic activity. High Alt Med Biol 2002, 3:167–176.
20. Simon HU, Grotzer M, Nikolaizik K, Blaser M, Schöni H: High altitude climate
therapy reduces peripheral blood T-lymphocyte activation, eosinophilia
and bronchial abstruction in children with house-dust mite allergic
asthma. Pediatr Pulmonol 1994, 17:302–311.
21. Pürschel W, Pahl O: Behaviour of eosinophilic granulocytes, total IgE and
allergen specific IgE antibodies in atopic neurodermitis during hospital
treatment of the North Sea climate. Z Hautkr 1985, 60:661–670.
22. Remes S, Korppi M, Remes K, Savolainen K, Mononen I, Pekkanen J: Serum
eosinophil cationic protein (ECP) and eosinophil protein X (EPX) in
childhood asthma: the influence of atopy. Pediatr Pulmonol 1998,
25:167–174.
23. Engst R, Vocks E: High-mountain climate therapy for skin diseases and
allergy: Mode of action, therapeutic results, and immunologic effects.
Rehabilitation (Stutg) 2000, 39:215–222.
24. Angelova-Fischer I, Hipler UC, Bauer A, Fluhr JW, Tsankov N, Fischer TW,
Elsner P: Significance of interleukin-16, macrophage-derived chemokine,
eosinophil cationic protein and soluble E-selectin in reflecting disease
activity of atopic dermatitis – from laboratory parameters to clinical
score. Br J Dermatol 2006, 154:1112–1117.
25. Masuda K, Katoh N, Okuda F, Kishimoto S: Increased levels of serum
interleukin-16 in adult type atopic dermatitis. Acta Derm Venereol 2003,
83:249–253.
doi:10.1186/2045-7022-4-17
Cite this article as: Eberlein et al.: Influence of alpine mountain climate of
Bavaria on patients with atopic diseases: studies at the Environmental
Research Station Schneefernerhaus (UFS - Zugspitze) – a pilot study.
Clinical and Translational Allergy 2014 4:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
